Literature DB >> 16854957

Relationship between the number of different antibiotics used and the total use of antibiotics in European hospitals.

Fiona M MacKenzie1, Dominique L Monnet, Ian M Gould.   

Abstract

OBJECTIVES: The aim of this study was to establish whether there was a relationship between the number of antibacterial agents used and total antibiotic use in European hospitals.
METHODS: A total of 139 hospitals from 30 countries supplied data on antibiotic use (ATC group J01) for 2001, expressed as the number of defined daily doses per 100 occupied bed-days (DDD/100 BD) and also numbers of different antibiotics used.
RESULTS: Participating hospitals used a median of 46 antibiotics in 2001 (range 16-82). The most frequently used antibiotic per hospital accounted for a median of 16.5% (range 7.2-60.9%) of total use and the 10 most frequently used agents accounted for a median of 73.7% (range 53.0-98.5%) of total use. Numbers of antibiotics used varied significantly by European geographical region (Kruskal-Wallis test, P = 0.001). The median total antibiotic use was 49.6 DDD/100 BD. A statistically significant relationship was found between the number of antibiotics used and total antibiotic use (Spearman's rank, r = 0.40 and P < 0.01) for all hospitals. Individual correlations were significant in Western (r = 0.57, P < 0.01) and Southern Europe (r = 0.67, P < 0.01) only.
CONCLUSIONS: The quantitative use of antibiotics in European hospitals was highly variable as was the number of different antibiotics used. In the two areas exhibiting highest total use, the greater the number of antibiotics used, the higher the total use of these drugs. Intervention studies are now needed to ascertain whether or not successful antibiotic restriction policies can reduce total antibiotic use and subsequently reduce antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16854957     DOI: 10.1093/jac/dkl286

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Regional differences in symptomatic fever management among paediatricians in Switzerland: the results of a cross-sectional Web-based survey.

Authors:  Sebastiano A G Lava; Giacomo D Simonetti; Alessandra Ferrarini; Gian Paolo Ramelli; Mario G Bianchetti
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  Complicated community-acquired soft tissue infection by MRSA from porcine origin.

Authors:  Ph Declercq; D Petré; B Gordts; A Voss
Journal:  Infection       Date:  2007-10-31       Impact factor: 3.553

Review 3.  Optimization of antibiotic use in hospitals--antimicrobial stewardship and the EU project ABS international.

Authors:  Franz Allerberger; Arno Lechner; Agnes Wechsler-Fördös; Roland Gareis
Journal:  Chemotherapy       Date:  2008-07-31       Impact factor: 2.544

Review 4.  Antibiotic stewardship through the EU project "ABS International".

Authors:  Franz Allerberger; Annegret Frank; Roland Gareis
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Probiotic Lactobacillus reuteri Prevents Postantibiotic Bone Loss by Reducing Intestinal Dysbiosis and Preventing Barrier Disruption.

Authors:  Jonathan D Schepper; Fraser L Collins; Naiomy Deliz Rios-Arce; Sandi Raehtz; Laura Schaefer; Joseph D Gardinier; Robert A Britton; Narayanan Parameswaran; Laura R McCabe
Journal:  J Bone Miner Res       Date:  2019-01-28       Impact factor: 6.741

Review 6.  Antibiotic prescription and prevalence rate in the outpatient paediatric population: analysis of surveys published during 2000-2005.

Authors:  Alessandra Rossignoli; Antonio Clavenna; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2007-09-21       Impact factor: 2.953

7.  Consumption of antibiotics in Chinese public general tertiary hospitals (2011-2014): Trends, pattern changes and regional differences.

Authors:  Xiaoyuan Qu; Chang Yin; Xihong Sun; Shusheng Huang; Chaofan Li; Panpan Dong; Xiufang Lu; Zhuo Zhang; Aitian Yin
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.